Photo taken from fiercepharma.com
Jul 12, 2024, 23:07
Osimertinib could change the standard of care for EGFR-mutant NSCLC
Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X:
“Osimertinib could change the standard of care for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).
The LAURA trial showed that osimertinib improves progression-free survival (PFS) in patients with unresectable NSCLC, reducing the risk of progression or death by 84% vs. placebo.
The median PFS was 39.1 months vs. 5.6 months.
The most common adverse events were radiation pneumonitis, diarrhea, and rash.”
For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines
Source: Iván R. González/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22